

Appl. No. 10/810,296
Dated April 10, 2008

Reply to Office action of April 5, 2008

REMARKS

Based on the Office action of April 5, 2008, claims 1, 2 and 9 have been amended and previously presented claims 3-8 and 10 remain in this application.

Each of all dependent claims 2-10 only references or depends from one claim.

Amendments to claims 1, 2 and 9 are based on the Office action and following facts:

1. This invention is used to produce a screening report consisting of a total risk, a risk level, a primary cause in the disease, a primary therapy target, a secondary therapy target and a therapy efficiency to the individual who requests the therapy to prevent or treat atherosclerosis-related CHD and stroke, as indicated in the examples 1-5 in pages 7-8 of specification and Figure 2 of the application, which results in all text of the screening report must present in independent claim 1 because the text is the object of this invention.

2. The equations 1 and 2 presented in enclosed pages 7-8 of the Office action are unable to yield

Appl. No. 10/810,296
Dated April 10, 2008

Reply to Office action of April 5, 2008

the disease risks R_1 and R_2 because the variables Jm_1 , Jm_2 , Jn_1 and Jn_2 of these equations are undetermined, which results in the previously presented equations 1-9 remain in claim 2. Substituting the measured values and normal values of nine atherosclerotic parameters into the remained equations 1-9 in claim 2 yield the nine disease risks R_1 - R_9 .

3. The labels and unique subscripts to all variables in claims 2 and 9 have been given according to the Office action.

4. A repeating of "substituting the measure values Cm_1 , Cm_2 into equation 1.1 yield Jm_1 , Jm_2 and substituting the normal values Cn_1 , Cn_2 into equation 1.1 yield Jn_1 , Jn_2 " is presented in enclosed pages 8-9 of the Office action. The repeating has been eliminated in claim 2.

These facts indicate it is unnecessary to amend further the claim of the application after the text and form of the claim have been allowed by the two primary examiners of USPTO.

The method of this invention is based on reliability theory background and major clinic and physiology evidences (see the cited references [1]-

Page 31 of 32

Page 32 of 32


Appl. No. 10/810,296
Dated April 10, 2008

Reply to Office action of April 5, 2008

[22] of specification of the application). For example, the method is based on conservation principles of mass, momentum and energy and the equations (1.1)-(1.3) in claim 1 are derived from the conservation principles (see the reference [1]). This invention is strongly supported by the latest review article in atherosclerosis research (Rader et al. Translating molecular discoveries into new therapies for atherosclerosis, Nature, 21 Feb 2008, Vol.451, pp.904-913).

The US patent application has been over 4 years since filed March 27, 2004. The applicant appreciates it if the Notice of Allowance is issued in this case soon.

Respectfully submitted,



Xing F. Wang, Ph.D.
Applicant
TEL: (774)239-3884
Fax: (508)831-0592

Encl.: the Office action of April 5, 2008 (8 sheets).